基于美沙酮的加速康复外科方案在DIEP皮瓣乳房再造中的4年分析
本研究评估纽约长老会/威尔康奈尔基于美沙酮的加速康复外科(ERAS)方案在DIEP皮瓣乳房再造中的应用。回顾性非ERAS队列(2017-2020,163例)与前瞻性ERAS队列(2021-2024,216例)对比显示,ERAS组住院时间更短、疼痛评分更低、心动过速发生率更低,住院阿片类药物消耗减少51.4%,出院阿片处方减少22.2%。ERAS组出院后14天内阿片使用平均70.78 MME,中位停药时间3.0天。
要点
- 基于美沙酮的ERAS方案可缩短DIEP皮瓣乳房再造患者住院时间并降低疼痛评分。
- ERAS组住院阿片消耗减少51.4%,出院阿片处方减少22.2%。
- ERAS组出院后阿片使用中位停药时间为3.0天。
核心结论
- 实施基于美沙酮的ERAS方案显著改善了DIEP皮瓣乳房再造患者的康复结局。
研究设计与样本
- 单中心回顾性非ERAS队列(2017-2020年,163例)与前瞻性ERAS队列(2021-2024年,216例)的对比分析。
主要发现
- ERAS组住院时间2.97天 vs 非ERAS组3.37天(P<0.001)。
- ERAS组平均疼痛评分2.37 vs 3.18(P<0.001),峰值疼痛评分6.23 vs 7.47(P<0.001)。
- ERAS组心率85.5 vs 95.6(P<0.001),心动过速发生率10.7% vs 28.2%(P<0.001)。
- 住院阿片消耗减少51.4%(208.02 vs 101.02 MME),出院阿片处方减少22.2%(194.21 vs 151.83 MME,P<0.001)。
- ERAS组216份问卷中76份(35.19%)回复,出院后阿片使用平均70.78 MME,中位停药时间3.0天。
临床怎么用
- 可考虑在DIEP皮瓣乳房再造中采用基于美沙酮的ERAS方案以改善疼痛控制并减少阿片消耗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This study evaluates the effectiveness of the New York--Presbyterian/Weill Cornell methadone-based enhanced recovery after surgery (ERAS) protocol in reducing postoperative pain and narcotic consumption in patients undergoing deep inferior epigastric perforator flap breast reconstruction. METHODS: This study includes a retrospective non-ERAS cohort (2017 to 2020) and a prospective ERAS cohort (2021 to 2024) of consecutive patients undergoing deep inferior epigastric perforator flap breast reconstruction at a single institution. Outcomes assessed included postoperative complications, length of hospital stay, vital signs, pain scores, opioid consumption, and outpatient opioid prescriptions after discharge. In addition, ERAS patients were surveyed on home opioid use for 14 days after discharge. RESULTS: A total of 216 patients from the ERAS group and 163 patients from the non-ERAS group were included. Patients in the ERAS group had a significantly shorter length of hospital stay (2.97 versus 3.37 days, P < 0.001) and lower average pain scores (2.37 versus 3.18, P < 0.001), peak pain scores (6.23 versus 7.47, P < 0.001), heart rates (85.5 versus 95.6, P < 0.001), and incidences of tachycardia (10.7% versus 28.2%, P < 0.001). Inpatient opioid consumption decreased by 51.4% (208.02 versus 101.02 morphine milligram equivalents [MMEs]), and outpatient opioid prescriptions were reduced by 22.2% (194.21 versus 151.83 MMEs, P < 0.001). Of the 216 surveys distributed to the patients in the ERAS group, 76 responses (35.19%) were received. Postdischarge opioid use averaged 70.78 MMEs. The median time to cessation was 3.0 days. CONCLUSIONS: Implementation of the New York--Presbyterian/Weill Cornell methadone-based ERAS protocol significantly improved recovery outcomes. These findings underscore the potential of methadone to enhance traditional ERAS protocols, supporting its broader adoption in plastic surgery.
引用
- Qin N, Wei L, Gundlach C, et al. Methadone-Based Enhanced Recovery after Surgery Protocol in DIEP Flap Breast Reconstruction: A 4-Year Analysis. Plast Reconstr Surg. 2026. PMID: 42647871. doi:10.1097/PRS.0000000000012635
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。